All questionsGuidelines: Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer1 question · 2 sourcesGuidelinesDoes NCCN recommend TRODELVY for metastatic TNBC?“National Comprehensive Cancer Network® (NCCN®): Sacituzumab govitecan-hziya (TRODELVY) is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or mTNBC with PD-L1 CPS <10b or who are not candidates for PD-1/PD-L1 inhibitor therapy and with no germline BRCA1/2 PVc as first-line therapy.d” (opens the source at this quote in a new tab)CopyFlag“NCCN: Sacituzumab govitecan-hziy (TRODELVY) in combination with pembrolizumab is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or mTNBC who are PD-L1 CPS ≥10,b regardless of germline BRCA1/2 PV status,c as first-line therapy.d” (opens the source at this quote in a new tab)CopyFlag“National Comprehensive Cancer Network® (NCCN®): Sacituzumab govitecan-hziy (TRODELVY) is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or mTNBC as second-line therapy. It may be considered for later line if not used as second-line therapy.” (opens the source at this quote in a new tab)CopyFlag“The NCCN recommendations differ from the sacituzumab govitecan-hziy (TRODELVY) Prescribing Information.” (opens the source at this quote in a new tab)CopyFlag